Latest European Market News

Evion Group has landed a significant A$1.5 million order to supply expandable graphite to a major US graphite supply chain company, reinforcing its position as a trusted non-Chinese supplier amid growing demand.

SDI Limited reported a steady FY2025 with a slight profit increase, driven by growth in aesthetic and whitening products and the launch of its new amalgam replacement, Stela. The company also announced plans for a new factory to boost production capacity.

Provaris Energy’s 2025 AGM highlights strategic progress in hydrogen and CO2 storage technologies, focusing on European market expansion and a refined licensing business model.

Little Green Pharma Ltd reported a 9.6% revenue increase to $19.2 million and slashed its net loss by 73% in the half-year ending September 2025, driven by strong growth in European medicinal cannabis markets.

James Hardie Industries reports a 34% jump in Q2 FY26 net sales driven by the AZEK acquisition and European growth, while grappling with margin pressures and integration costs.

ECS Botanics has successfully raised nearly A$2 million through a placement aimed at accelerating its international expansion and product development. The move underscores growing investor confidence in the medicinal cannabis company’s strategic growth plans.

Krakatoa Resources reports significant progress in drilling at its Zopkhito Antimony-Gold Project in Georgia, with most holes intersecting visible antimony mineralisation. Assay results are eagerly awaited to validate historical resource estimates and support a maiden JORC-compliant Mineral Resource.

Dyno Nobel Limited reported a robust 23% increase in EBIT for FY25, driven by strong explosives performance and transformation initiatives, while progressing its fertilisers separation and setting ambitious sustainability targets.

Memphasys Limited has successfully raised over $1.1 million through a pro-rata entitlement offer to accelerate the commercialisation of its innovative Felix™ sperm selection system, targeting key regulatory approvals and market expansion.

AVITA Medical reported a 13% drop in Q3 commercial revenue to $17.1 million but improved its net loss and secured CE Mark approval for RECELL GO in Europe, signaling strategic shifts ahead.

ReNerve Limited is scaling up its clinical trial for the NervAlign® Nerve Cuff following promising interim results that show significant pain reduction in nerve repair patients. The expanded study aims to solidify evidence for broader regulatory approval and market adoption.

DTI Group secures a major $2 million contract with Rio Tinto for autonomous locomotive tech and re-enters the European market through a new agreement with CAF.